Search Results

You are looking at 161 - 170 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

Emerging Treatment Options for B-Cell Lymphomas

Andrew D. Zelenetz

%. The phase II GAUSS study 2 was the first head-to-head study of obinutuzumab versus rituximab in patients with relapsed indolent NHL with a prior response to rituximab. Although a trend toward higher response rates was seen with obinutuzumab, no

Full access

The Role of Hematopoietic Stem Cell Transplant in Follicular Lymphoma

Edward A. Faber Jr. and Julie M. Vose

Initial reports with myeloablative allogeneic HCT show an improvement in relapse/progression compared with autologous HCT, but this improvement is associated with intolerable nonrelapse mortality (NRM). To reduce toxicities associated with high NRM

Full access

After Local Therapy for Esophageal Cancer, Should We Continue to Survey Patients and, If So, Why and How?

Jaffer A. Ajani

surveillance. Whether certain groups of patients benefit from surveillance remains conjectural because of the lack of data. We can make a major distinction in the rates of locoregional relapse among patients who receive trimodality versus bimodality therapies

Full access

Non-Hodgkin’s Lymphomas, Version 3.2012

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Maoko Naganuma, and Mary A. Dwyer

randomized trial is comparing outcomes between chemoimmunotherapy with FCR and BR in “fit” patients with previously untreated CLL (CLL10 study). The BR regimen was also active (ORR, 59%; CR, 9%) in patients with relapsed/refractory disease (N= 78) in a

Full access

Multiple Myeloma: New Uses for Available Agents, Excitement for the Future

Kenneth C. Anderson

use current agents, according to recommendations in the 2015 NCCN Guidelines: Panobinostat/bortezomib/dexamethasone as a category 1 option for relapsed myeloma in patients who have received at least 2 prior regimens, including bortezomib and an

Full access

Novel Therapies in the Treatment of Multiple Myeloma

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

1986 ; 105 : 8 – 11 . 20 Gertz MA Garton JP Greipp PR . A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma . Leukemia 1995 ; 9 : 2115 – 2118 . 21 Gertz MA Kalish LA Kyle RA . Phase III

Full access

Highlights of the NCCN Oncology Research Program

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Principal

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed